IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
Zhu, Hong-Hu1; Zhang, Xiao-Hui1; Qin, Ya-Zhen1; Liu, Dai-Hong1; Jiang, Hao1; Chen, Huan1; Jiang, Qian1; Xu, Lan-Ping1; Lu, Jin1; Han, Wei1; Bao, Li1; Wang, Yu1; Chen, Yu-Hong1; Wang, Jing-Zhi1; Wang, Feng-Rong1; Lai, Yue-Yun1; Chai, Jun-Yue2; Wang, Li-Ru3; Liu, Yan-Rong1; Liu, Kai-Yan1; Jiang, Bin1; Huang, Xiao-Jun1,4
刊名BLOOD
2013-05-16
DOI10.1182/blood-2012-11-468348
121期:20页:4056-4062
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
关键词[WOS]ACUTE MYELOID-LEUKEMIA ; MINIMAL RESIDUAL DISEASE ; STEM-CELL TRANSPLANTATION ; PROGNOSTIC VALUE ; MARROW-TRANSPLANTATION ; AML1-ETO-POSITIVE AML ; KIT MUTATIONS ; GROUP-B ; RQ-PCR ; INV(16)
英文摘要

We aimed to improve the outcome of t(8;21) acute myeloid leukemia (AML) in the first complete remission (CR1) by applying risk-directed therapy based on minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels. Risk-directed therapy included recommending allogeneic hematopoietic stem cell transplantation (allo-HSCT) for high-risk patients and chemotherapy/autologous-HSCT (auto-HSCT) for low-risk patients. Among 116 eligible patients, MRD status after the second consolidation rather than induction or first consolidation could discriminate high-risk relapse patients (P = .001). Allo-HSCT could reduce relapse and improve survival compared with chemotherapy for high-risk patients (cumulative incidence of relapse [CIR]: 22.1% vs 78.9%, P < .0001; disease-free survival [DFS]: 61.7% vs 19.6%, P = .001), whereas chemotherapy/auto-HSCT achieved a low relapse rate (5.3%) and high DFS (94.7%) for low-risk patients. Multivariate analysis revealed that MRD status and treatment choice were independent prognostic factors for relapse, DFS, and OS. We concluded that MRD status after the second consolidation may be the best timing for treatment choice. MRD-directed risk stratification treatment may improve the outcome of t(8; 21) AML in CR1. This trial was registered at http://www.chictr.orgas #ChiCTR-OCH-12002406.

语种英语
WOS记录号WOS:000321871900010
项目编号81230013 ; Z111107067311070
资助机构National Natural Science Foundation of China ; Ministry of Health (China) ; Beijing Municipal Science and Technology Commission
引用统计
被引频次:93[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50961
专题北京大学第二临床医学院_血液科
作者单位1.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
2.Beijing 6 Hosp, Beijing, Peoples R China
3.Beijing Rehabil Hosp, Beijing, Peoples R China
4.Peking Univ, Inst Hematol, Peking Univ Peoples Hosp, Beijing 10044, Peoples R China
推荐引用方式
GB/T 7714
Zhu, Hong-Hu,Zhang, Xiao-Hui,Qin, Ya-Zhen,et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial[J]. BLOOD,2013,121(20):4056-4062.
APA Zhu, Hong-Hu.,Zhang, Xiao-Hui.,Qin, Ya-Zhen.,Liu, Dai-Hong.,Jiang, Hao.,...&Huang, Xiao-Jun.(2013).MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.BLOOD,121(20),4056-4062.
MLA Zhu, Hong-Hu,et al."MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial".BLOOD 121.20(2013):4056-4062.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhu, Hong-Hu]的文章
[Zhang, Xiao-Hui]的文章
[Qin, Ya-Zhen]的文章
百度学术
百度学术中相似的文章
[Zhu, Hong-Hu]的文章
[Zhang, Xiao-Hui]的文章
[Qin, Ya-Zhen]的文章
必应学术
必应学术中相似的文章
[Zhu, Hong-Hu]的文章
[Zhang, Xiao-Hui]的文章
[Qin, Ya-Zhen]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。